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Purpose: We have shown that nonlinear optical corneal crosslinking (NLO CXL) and
stiffening can be achieved in ex vivo rabbit corneas using an 80-MHz, 760-nm
femtosecond (FS) laser, however the required power was beyond the American
National Standard Institute limit. The purpose of this study was to test the efficacy of
amplified FS pulses to perform CXL to reduce power by increasing pulse energy.
Methods: A variable numerical aperture laser scanning delivery system was coupled
to a 1030-nm laser with a noncollinear optical parametric amplifier to generate 760
nm, 50 to 150 kHz amplified FS pulses with 79.5-lm axial and 2.9-lm lateral two-
photon focal volume. Ex vivo rabbit corneas received NLO CXL, and effectiveness was
assessed by measuring collagen autofluorescence (CAF) and mechanical stiffening.
NLO CXL was also performed in 14 live rabbits, and changes in corneal topography
were measured using an Orbscan.
Results: Amplified pulses (0.3 lJ) generated significant CAF that increased
logarithmically with decreasing scan speed; achieving equivalent CAF to UVA CXL
at 15.5 mm/s. Indentation testing detected a 62% increase in stiffness compared to
control, and corneal topography measurements revealed a significant decrease of 1.0
6 0.8 diopter by 1 month (P , 0.05).
Conclusions: These results show that NLO CXL using amplified pulses can produce
corneal collagen CXL comparable to UVA CXL.
Translational Relevance: NLO CXL using amplified pulses can produce corneal CXL
comparable to UVA CXL, suggesting a potential clinical application in which NLO CXL
can be used to perform personalized crosslinking for treatment of refractive errors and
keratoconus.
Introduction
Myopia is the most common refractive error and is
estimated to affect 1.6 billion people worldwide, with
a prevalence of 33% in the United States and up to
80% to 90% in East Asian young adults.1,2 Since its
introduction nearly 30 years ago, laser-assisted in situ
keratomileusis (LASIK) has become the standard of
care for surgical correction of refractive errors.3 The
procedure entails cutting a corneal flap and ablating
the stroma underneath with an excimer laser, thus
modifying corneal curvature to better focus light back
onto the retina. Despite high patient satisfaction rates
of LASIK (.95%),4 many patients, such as those with
thin corneas, suspected keratoconus, or those with
mild refractive errors, are not ideal candidates for the
procedure. Specifically, in patients with low refractive
error (62 diopters), the risks associated with cutting
the LASIK flap may outweigh the benefits of a
successful surgery. These patients can typically
function day to day uncorrected, opting to wear
glasses only during certain activities such as driving.
This creates an unmet medical need for a noninvasive,
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safer procedure for the correction of low refractive
errors.
In recent years, a number of technologies have
emerged with the potential to address the issue of a
safer, less-invasive refractive surgery for low refrac-
tive errors by avoiding cutting of a flap. The first
technology in this category, ultraviolet A (UVA)
corneal collagen crosslinking (CXL), was initially
developed in the early 2000s as a treatment for
keratoconus, but it has been increasingly investigated
as a refractive procedure.5,6 UVA CXL uses UVA
light to photoactivate riboflavin (previously imbibed
into the stroma via eye drops), thus generating an
excited triplet state of riboflavin, free oxygen radicals,
and subsequent crosslinking of collagen fibrils. With
respect to keratoconus, the goal of CXL is to halt the
progression of the disease by strengthening the
cornea. In regard to potential refractive CXL, the
goal is to selectively alter the biomechanical proper-
ties of the corneal stroma via collagen crosslinks,
thereby changing the topography of the cornea and
correcting vision.
While UVA CXL is the most commonly used
method to achieve corneal CXL, the use of femtosec-
ond (FS) lasers has also gained interest in recent
years. Wozniak et al.7 utilized blue (480 nm) FS pulses
to induce a refractive index change in corneal tissue,
while Wang et al.8 reported corneal CXL without
riboflavin using infrared pulses. The nature of these
two methods, however, is not directly based on the
original UVA CXL methodology, and therefore
explanations of the principles underlying these
techniques are not fully understood. Our group has
previously used an 80 MHz FS laser oscillator tuned
to 760 nm to crosslink corneal collagen via nonlinear
two-photon excitation of riboflavin, a technique
referred to as nonlinear optical collagen crosslinking
(NLO CXL).9–11 NLO CXL uses two photons of near
infrared FS laser light (with a combined energy of one
UVA photon) to excite riboflavin, thus generating
oxygen free radicals and subsequent collagen cross-
linking, similar to UVA CXL. However, this tech-
nique is distinctly different from UVA CXL in that
the excitation of riboflavin, and thus crosslinking,
only occurs in the well-defined and specifically chosen
two-photon focal volume of the laser delivery
objective. The location of the focal volume can be
arbitrarily scanned with micrometer precision to
achieve a crosslinking area of any geometry and
depth within the cornea. While we achieved corneal
CXL and mechanical stiffening on par with UVA
CXL, these studies used a high repetition rate (80
MHz) low-pulse energy (10 nJ) laser requiring a high
average power (~800 mW), well above the American
National Standards Institute (ANSI) limit of 46.1
mW.12
To address this issue and reduce the average power
exposure to a clinically acceptable level, this study
explored using regeneratively amplified FS laser
pulses (microjoule pulse energy) at low repetition
rates (kilohertz) to precisely crosslink corneal collagen
while remaining under the ANSI limit of 46.1 mW. By
increasing pulse energy from 10 nJ to 1 lJ, it was
expected that the average total energy could be
proportionally reduced from 800 to 8 mW. This was
verified in ex vivo eyes after treatment with a 5 kHz
amplified FS laser using the presence of collagen
autofluorescence (CAF) as an indicator that CXL had
occurred.
Following preliminary experiments using 1-lJ
pulse energies, a custom noncollinear optical para-
metric amplifier (NOPA) was designed and built to
deliver 760 nm amplified FS laser pulses at repetition
rates of 50 to 150 kHz. Amplified NLO CXL was
performed in ex vivo rabbit eyes, after which collagen
autofluorescence and mechanical stiffness measure-
ments were performed. Crosslinking experiments were
also carried out in live rabbits, and topography was
measured to assess refractive outcomes of amplified
NLO CXL.
Methods
Proof of Concept
Prior to building a custom amplified NLO CXL
system, the question of whether NLO CXL was even
possible using amplified FS pulses was determined by
examining CAF within ex vivo rabbit eyes treated by
coupling our delivery optics with an amplifier system
(Legend-F Titanium Sapphire Regenerative Amplifi-
er; Coherent, Inc., Santa Clara, CA). This 5-kHz, 130-
FS, 800-nm laser light was directed through an optical
parametric amplifier (OPA) (Opera-LE-F OPA;
Coherent, Inc.) to produce 1520-nm laser light that
was then frequency doubled using a beta barium
borate (BBO) crystal to produce a 760-nm beam with
1-lJ pulse energy. FS pulses were then focused into
our previously described delivery device that uses a
patented, low numerical aperture focusing system to
generate enlarged two-photon volumes of 2 to 3 lm in
diameter and 100 lm in axial length, as previously
described.10,11
Using the 5-kHz repetition rate, ex vivo rabbit
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corneas were raster scanned over a 4-mm-diameter
area at a scan speed of 15 mm/s to produce single
pulse, 2- to 3-lm-diameter CAF spots with a 3-lm
spot separation using a total power of only 5 mW.
Corneas were then removed from the eye and fixed in
2% paraformaldehyde (PFA) in PBS, pH 7.2,
overnight prior to two-photon detection of corneal
CAF using a multiphoton confocal microscope (Zeiss
510; Carl Zeiss, Jena, Germany) and FS laser
(Chameleon; Coherent, Inc.) as previously de-
scribed.10,11,13 Briefly, the presence of CAF was
detected using 760-nm FS laser light to induce two-
photon excited blue light 400- to 450-nm CAF from
crosslinked regions of the cornea. CAF was examined
within both vibratome cross sections and whole
mount corneas viewed en face or parallel to the
corneal surface (Fig. 1). Similar tissue preparation
and imaging were performed for detection of CAF in
later studies. The presence of CAF within these
samples was used as justification for building a more
stable system with a higher repetition rate, able to
crosslink at faster speeds.
Amplified FS Laser and Delivery
Though commercially available FS oscillators are
broadly tunable and can readily deliver 760-nm FS
laser pulses, commercial turnkey amplified FS laser
systems are not available at this wavelength. Howev-
er, photons of different wavelengths can be generated
from an FS laser source using nonlinear processes in
an OPA. In this study, we used a commercially
available amplified FS laser operating at 1030 nm
(One Five Origami; NKT Photonics, Birkerod, Den-
mark), with a variable repetition rate (50–150 kHz),
318-FS pulse duration, and 4-W average power as the
laser source for a lab-built NOPA. The NOPA
generated variable microjoule pulses of 760-nm FS
light, which were then aligned into the beam delivery/
scanning device from our previous study10 and then
into the eye. An overview of the entire system is
presented in Figure 2. In general, a NOPA is a device
capable of converting a pump photon of a specific
wavelength into two photons of longer wavelengths,
termed signal and idler. The wavelengths of the signal
and idler can be continuously tuned as long as the
requirement of energy conservation is met. The
NOPA built for this study contains three stages:
supercontinuum generation, formation of the pump
beam, and parametric conversion.
Stage 1: Supercontinuum Generation
Approximately 10% of the output of the 1030-nm
laser source is picked off by a beam splitter and
focused onto a 200-lm-thick sapphire plate (Fig. 2,
stage 1). Acting as a nonlinear medium, this spectrally
broadens the original laser pulse via self-phase
modulation, creating supercontinuum radiation that
appears like white light to the eye. Centered at 1030
nm, the supercontinuum radiation contains spectral
components from 500 to 1500 nm. The output is well-
formed and smoothly varying, making it a suitable
source to serve as the ‘‘seed’’ pulse for the OPA. The
white light is passed through two water cuvettes,
adding group velocity dispersion to the supercontin-
uum and ultimately reducing the bandwidth of the
760-nm OPA output to 12 nm.
Stage 2: Pump Formation
After the 10% beam splitter, the remaining 1030-
nm source beam is sent to a 2-mm-thick BBO crystal
for frequency doubling (Fig. 2, Stage 2). The 2-mm
BBO is responsible for converting the source from
1030 to 515 nm, which can then be used to generate
the two longer wavelength photons in the visible
spectrum. BBO is used due to its large second-order
susceptibility, v2, as well as its high damage threshold.
Stage 3: Parametric Conversion
After frequency doubling in stage 2, the 515-nm
radiation is sent to a second 400-lm-thick BBO
crystal (Fig. 2, stage 3) for parametric conversion.
After passing through the second BBO crystal, the
515-nm light produces a parametric ring of visible
radiation. As the crystal angle is varied, color
separation can be observed within the ring. The
proper crystal angle is determined by finding the angle
Figure 1. CAF of single spot amplified NLO CXL. The image
shown in (A) demonstrates the CAF within a vibratome section of a
cornea treated with three separate layers of single spot amplified
NLO CXL. (B) The en face view of a cornea treated in the same way.
A grid of CAF spots can clearly be seen within the sample, and
each spot represents CXL from a single amplified pulse.
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that minimizes color separation. Once this angle is
found, the supercontinuum seed from stage 1 is
spatially overlapped with the 515-nm pump in the
second BBO crystal and directionally overlapped with
the parametric ring. After this is accomplished, the
translation stage shown in Figure 2 (delay 1) is
adjusted to ensure proper temporal overlap between
the seed pulse and the 515-nm pump pulse. When
both the seed and pump pulses are aligned spatially,
directionally, and temporally, the parametric ring of
radiation collapses into a beam that takes on the
properties of the original pump beam. Owing to the
fact that the supercontinuum seed is chirped, wave-
length tuning can be accomplished by altering the
timing of the seed relative to the pump pulse by
adjusting delay 2 (Fig. 2). For this study, the center
wavelength of the NOPA was adjusted to 760 nm with
a full width at half maximum (FWHM) bandwidth of
12 nm, as measured by a spectrometer (Thorlabs,
Newton, NJ). The pulse duration of the newly formed
760-nm beam was measured using a lab-built auto-
correlator and found to be ~700 FS. The beam is then
passed twice through an SF10 ultrafast laser disper-
sion compensation prism pair (DCP 1 and 2), which
has the effect of compressing the pulse and thus
controlling pulse duration. After compression, the
pulse duration was measured to be ~400 FS.
Laser Delivery
Upon leaving the pulse compressor, the beam
passes through a half wave plate (k/2) and polarizing
beam cube that function as a continuously variable
beam attenuator. The rest of the beam delivery optics
are identical to those used in our previous study.10
Briefly, the beam passes through a variable expanding
telescope before entering a series of galvo steering
mirrors that together scan the beam in a prepro-
grammed raster pattern at a preprogrammed speed.
The beam then passes through a second expanding
telescope before being directed down into the
objective and through the applanation glass and into
the cornea. The effective numerical aperture of the
delivery system used in this study was 0.12, which
would theoretically result in a focal volume with axial
and lateral dimensions of 79.5 and 2.9 lm, respec-
tively, as calculated using Zipfel’s equations.14
Amplified NLO CXL in the Ex Vivo Rabbit
Cornea
After confirming crosslinking using amplified FS
pulses was possible, it was necessary to determine the
amount of amplified FS pulse energy needed to
achieve corneal crosslinking at levels equal to
standard UVA CXL. The amount of energy deposi-
Figure 2. Custom NOPA schematic. Schematic shows the components of the amplified NLO CXL device. The device consists of three
main elements: (1) The laser source (OneFive regeneratively amplified FS laser) produces 1030 nm amplified FS pulse light. (2) The NOPA
consisting of three stages (supercontinuum generation, frequency-doubled pump beam generation, and parametric conversion) is used
to alter the wavelength of the input beam to 760 nm. (3) The laser delivery system focuses the resulting 760 nm amplified FS light into
the eye. Amplified FS light is directed through the three NOPA stages using a series of mirrors (M) and specified focal length lenses (f),
through a dispersion compensation prism pair (DCP) for pulse compression, and then into the delivery optics.
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tion was controlled by varying the scan speed of the
laser beam and thus the amount of laser pulses per
unit area along the scan line. Previously, our group, as
well as others, has used CAF as a metric to assess the
degree of collagen crosslinking.9–11,15–17 The same
method was used in this study, with CAF being
compared against our previously published CAF data
using standard UVA CXL.13 After a suitable scan
speed was determined, we performed mechanical
testing to determine the effect of amplified NLO
CXL on tissue stiffness.
Scan Speed Versus CAF
A total of 29 rabbit eyes were shipped overnight on
ice (Pel-Freez Biologicals, Rogers, AR); experiments
were performed the same day as delivery. The
epithelium was mechanically removed in the central
8 mm of the cornea with a Tooke knife. The corneas
were then imbibed with riboflavin via eye drops
containing 0.5% riboflavin-5-phospate and 20% high
fraction dextran, molecular weight 450 to 650 kDa
(Sigma-Aldrich Corp., St. Louis, MO) in PBS
solution once every 2 minutes for 30 minutes. Next,
the eyes underwent amplified NLO CXL in the
central 4 mm of the cornea. Treatment groups were
defined by the scan speed of the laser beam, ranging
from 5 to 100 mm/s. The beam was scanned in a single
plane in a raster pattern as described previously, with
a line separation of 5 lm to shorten the scanning time
required for this portion of the study.10,11 The depth
of focus was set for 50 lm below the contact glass so
as to include the entire focal volume within the tissue.
The pulse energy and average power were set to 0.3 lJ
and 30 mW, respectively, at 50- to 100-kHz pulse
repetition frequency, well beneath the ANSI limit of
46.1 mW. The parameters for each treatment group as
well as each group size are outlined in Table 1. Each
group had at least three eyes (n ¼ 3). The treatment
times reported in this table were calculated for line
separations of both 2 and 5 lm, since the 5-lm
separation used for CAF evaluation was later reduced
to 2 lm for mechanical measurements and in vivo
treatments. The values for standard UVA CXL are
also provided for reference. After treatment, corneas
were prepared for CAF measurements.
CAF was measured per the protocol in our
previous studies, taking care to faithfully replicate
the measurements via laser power and microscope
settings to allow for reliable comparison.10 Briefly,
after amplified NLO CXL, corneas were excised from
the globe and fixed overnight in 2% PFA (Mallinck-
rodit Baker, Inc., Phillipsburg, NJ) in PBS at 48C. The
corneas were then sectioned into 250-lm-thick slices
perpendicular to the axis of crosslinking using a
vibratome (Campden Instruments, Loughborough,
England). The samples were then imaged for blue
CAF using a microscope (Zeiss LSM 510; Carl Zeiss)
and a Coherent FS laser as an excitation source. The
samples were excited at 760 nm while the CAF signal
was collected between 400 and 450 nm using a
bandpass filter.
The images were exported to image analysis
software (Metamorph; Molecular Devices, Sunny-
vale, CA), and three 1003 100 pixel areas within both
the central anterior crosslinked region and the
background region were identified. The average
intensities within both regions were then subtracted.
To compensate for the fact that line separation was
Table 1. Scan Speed and Total Energy
Scan
Speed, mm/s
Group
Size, n
5-lm Line Spacinga 2-lm Line Spacinga
Treatment
Duration, min
Total
Energy, J
Treatment
Duration, min
Total
Energy, J
100 3 0.53 0.96 1.33 2.4
80 3 0.67 1.2 1.67 3.0
60 3 0.89 1.6 2.22 4.0
40 3 1.33 2.4 3.33 6.0
30 4 1.64 2.96 4.11 7.4
20 6 2.66 4.8 6.66 12.0
10 3 4.93 8.88 12.33 22.2
5 4 9.86 17.76 24.66 44.4
UVA CXL NA NA NA 30 5.4
a Line separations of 5 lm were used for CAF analysis, whereas 2-lm separations were used for mechanical testing. All
NLO CXL treatments were performed over a 4-mm-diameter area.
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not continuous in the NLO CXL treatment, resulting
in dark areas between the scan lines (Fig. 3) that
would make the CAF data noncomparable to
previous UVA CXL CAF data, a percentage of
crosslinked area was calculated from the NLO CXL
samples using the FWHM values of a line scan
inserted across NLO CXL CAF images. This
percentage was used as a multiplication factor to
convert previously reported UVA CXL CAF data.13
Amplified NLO CXL and Corneal Stiffness
Based on the results from scan speed experiments,
a speed of 20 mm/s was chosen for the stiffness
experiments as this speed resulted in CAF comparable
to that of UVA CXL and still had reasonable
procedure time when the line separation was reduced
back to 2 lm. The total crosslinking time for this
speed was approximately 6.66 minutes (Table 1).
Mechanical measurements were conducted on corneas
that underwent amplified NLO CXL (seven eyes) as
well as control eyes (seven eyes). Three of the seven
NLO CXL eyes were excluded because CAF analysis
revealed the treatment region was outside the
measured area. Two of the seven control eyes were
excluded because their mechanical measurements
were measured more than two standard deviations
above the mean, indicating they were either old
corneas or had become dehydrated during testing.
The method used to measure mechanical stiffness was
needle microindentation and followed our previously
published protocol.10,18 Briefly, a 5 3 5-mm region
was excised around the pupil to ensure the crosslinked
region was present in the sample. Care was taken to
maintain the corneal thickness between 400 and 450
lm to minimize the effect of hydration on elasticity.
Next, the sample was placed under a 1-mm-diameter
flat tip force transducer probe that was attached to a
z-axis motorized controller. The probe was lowered
carefully until contact was made with the sample.
Once this start position was determined, the force
transducer tip was advanced into the sample to 10%
of the sample thickness for 10 cycles as precondition-
ing to determine the stress–strain relationship. An
elasticity value was calculated based on the peak force
value of the 10th cycle using the equations outlined by
Hayes et al.10,19,20
Live Rabbit Model
A total of 14 New Zealand albino rabbits under 6
months old were used in this study. They were divided
into two groups, five killed 2 weeks after treatment
and nine after 2 months. All animals were treated
according to the ARVO statement on the use of
animals in vision research, and experiments were
approved by the IACUC of the University of
California, Irvine. The right eye of each rabbit
underwent amplified NLO CXL whereas the left eye
served as a control. Both eyes of the short-term group
(2 weeks) were examined using in vivo confocal
microscopy through focusing (CMTF) imaging to
study cellular activity just prior to death and to
measure the corneal thickness and haze within the
stroma after treatment.13
For the long-term group (2 months), the corneal
topography was measured in both right and left eyes
using a topographer (Orbscan IIz; Bausch and Lomb,
Rochester, NY) 1 week prior to treatment (baseline)
and 1, 2, 4, and 8 weeks post treatment. The
topography measurements were performed by an
ophthalmologist (SWK) with previous experience in
topography measurements in the rabbit. Gaze fixa-
tion was achieved for these measurements by holding
the anesthetized animal while adjusting the machine
Figure 3. Amplified NLO CXL induced CAF. Example CAF images taken of ex vivo eyes treated with scanning speeds between 5 and 100
mm/s and line separation of 5 lm.
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to take the measurement. A minimum of three
complete scans were made for each eye at each time
point, Before all CMTF or topography procedures,
animals were anesthetized using a subcutaneous
injection of 30 to 50 mg/kg ketamine hydrochloride
(Hospira, Irvine, CA) and 5 to 10 mg/kg xylazine
(Akorn, Lake Forrest, IL). The effect of the
procedure was measured by calculating the difference
in refractive power, using a minimum of three
measurements per exam, between the right and left
eye at each time point (DD).
For amplified NLO CXL, sedated animals received
a drop of topical ophthalmic 0.5% tetracaine hydro-
chloride (Alcon, Ft. Worth, TX) to prevent pain. The
methods for epithelial removal and stromal riboflavin
delivery were identical to those used in the ex vivo
experiments described above. The right eyes then
underwent amplified NLO CXL in the central 4 mm
with a 2-lm line separation using a pulse energy and
average power of 0.3 lJ and 30 mW at a laser scan
speed of 20 mm/s. After treatment, the rabbits received
a subcutaneous 0.1 mL injection of buprenorphine
hydrochloride (Reckitt Benckiser Healthcare Ltd.,
Slough, UK) for pain. For 3 days following the
procedure, each rabbit received an antibiotic eye drop,
0.3% gentamicin sulfate (Allergan, Inc., Irvine, CA),
three times daily in the treated eye to prevent infection.
After either 2 weeks (five rabbits) or 8 weeks (nine
rabbits) post treatment, animals were euthanized via an
intravenous injection (Euthanasia III; Vedco, Inc., St.
Joseph, MO) into the marginal ear vein after the last
topography measurement. Immediately after death,
corneas were fixed in situ under 20 mmHg pressure via
perfusion of 2% PFA to maintain the in vivo collagen
structure, as described in previous studies.13 The
corneas were then excised and prepared for CAF
measurements in the same manner as described above
for ex vivo eyes to confirm the presence of crosslinking.
After CAF was examined, sections were stained with
phalloidin (1:100) and ethidium homodimer (2 lL/mL)
for fluorescent imaging of cellular structures as
described in previous studies.13
Statistics
Statistical analysis was performed using the Tukey-
Kramer method for a multiple comparison, 1-way or
repeated measures analysis of variance in statistical
software (MatLab; Mathworks, Natick, MA).
Groups were considered to have a statistically
significant difference with a P value of less than
0.05. In all figures, error bars represent standard
deviation.
Results
Ex Vivo Amplified NLO CXL
Scan Speed Versus CAF Intensity
Examples of CAF images used for measurements
are shown in Figure 3. The measured CAF intensities
corresponding to each treatment speed are graphed in
Figure 4. CAF intensity was scaled downward
logarithmically with increasing scan speed and fit to
the equation y ¼375.1ln(x) þ 1806.6 with an R2 ¼
0.9814. Using the FWHM values from a line scan
perpendicular through the crosslinked area of NLO
CXL CAF images, the percentage of crosslinked area
was measured to be 61.4%. Using Zipfel’s equations,14
a comparable theoretical value of 58% was calculated.
UVA CXL CAF values reported in a previous study
(1267 6 181)13 were converted to 777.9 6 111.1,
using this percentage to compensate for the spacing
between scan lines in NLO CXL CAF images.
Namely, only 61.4% of the UVA CXL CAF was
considered. Using this value, amplified NLO CXL
reached a comparable CAF intensity to UVA CXL at
a speed of 15.5 mm/s.
Corneal Stiffness
The indentation elasticity values of corneas treated
using amplified NLO CXL were measured to be 84.3
6 5.9 kPa (n ¼ 4), 1.62 times larger than control
values that averaged 52.2 6 8.6 kPa (n ¼ 5). After
Figure 4. CAF intensity versus scanning speed. CAF intensity of
amplified NLO CXL–treated eyes plotted with respect to increasing
scanning speed and compared to CAF of previously reported UVA
CXL data.13 The data fit the line y¼375.1ln(x)þ 1806.6 with an R2
value of 0.9814 and intersected the UVA CXL CAF line at a speed of
15.5 mm/s. Error bars represent standard deviation.
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statistical analysis, this difference was found to be
statistically significant (P , 0.05). A comparison of
these two values is provided in the graph in Figure 5.
In Vivo Amplified NLO CXL
Clinical observation of the corneas 48 hours after
treatment revealed very little irritation of the tissue.
No significant redness, swelling, or visible haze was
observed, as can be seen in Figure 6A. Figure 6B and
6C show a cross-sectional CMTF image and a 178-lm
deep plane image within a cornea at 2 weeks. The
scattering seen in Figure 6B and the spindle-shaped
cell bodies seen in Figure 6C indicate cellular
migration within the treated region at 2 weeks.
CMTF imaging within the short-term group also
revealed a significantly thicker epithelium (42.4 6 1.5
vs. 36.1 6 1.8 lm), an unchanged stromal thickness
(315.6 6 23.7 vs. 310.6 6 19.2 lm), and significantly
increased haze (3148.1 6 622 vs. 1303.1 6 527) in the
treated eye compared to control. Figure 6D shows
CAF taken within a vibratome section after 2 weeks
of healing. A consistent 110-lm-thick band of CAF
can be seen 90 lm below the surface of the epithelium.
Furthermore, cellular staining using phalloidin and
ethidium homodimer (Fig. 6E) revealed the presence
of keratocytes within the treated region of all samples.
This is noticeably different from the completely
acellular region seen in samples treated with UVA
CXL in previously reported studies.13
In the long-term group, corneal flattening was
measured as the diopter difference (DD) of the central
3 mm between the right and left eye (R-L) of each
rabbit prior to treatment and at the intervals listed
previously. For this reason, a negative value indicates
flattening of the treated eye. Corneal flattening was
also measured as the DD of each cornea compared to
baseline (DR or DL, respectively). Measurements of
two rabbits were excluded because CAF could not be
detected in the treated eye after sacrifice. Our
previous studies have shown that CAF is unchanged
even after 3 months of healing,13 so the lack of any
CAF was considered indicative of a lack of CXL.
There are various reasons this error may have
occurred. For example, the pupil may have been
misaligned during treatment, or the rabbit may have
slipped during the treatment. In either case, the
treatment would not have been located in the center
of the cornea and therefore was not measured in the
correct location in subsequent testing. Example
topography measurements of both control and
treated eyes, before and after treatment, are shown
in Figure 7. The average DD, DR, and DL from the
seven remaining rabbits are graphed in Figure 8 and
listed individually in Table 2. With the exception of
week 2 (P¼ 0.018), all time points showed significant
flattening compared to baseline. Additionally, all DR
measurements were significantly less than DL mea-
surements, indicating the treated cornea was flatten-
ing at a faster rate. With the exception of one rabbit
that showed a central acellular region, samples in
Figure 5. Elasticity after amplified NLO CXL. Amplified NLO CXL
(n ¼ 4) produced a 1.62-fold statistically significant increase in
corneal elasticity compared to control corneas (n ¼ 5) (P , 0.05).
Error bars represent standard deviation.
Figure 6. Short-term amplified NLO CXL. The image in (A) is a clinical image of the cornea 48 hours after treatment, showing very little
irritation. (B) A representative cross-sectional reconstruction of a CMTF stack taken at 2 weeks. (C) A single-plane CMTF image, 178 lm
deep, showing spindle-shaped cellular structures within the treatment region. (D) A representative CAF image showing a consistent
region of CAF and an intact, regrown epithelium. (E) Cells stained with phalloidin and ethidium homodimer within the CXL region.
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which CAF was detected after 2 months showed
increased cellular density throughout the crosslinked
region compared to those at 2 weeks, as shown in
Figure 9.
Discussion
Our previous method of NLO CXL using non-
amplified FS pulses was able to produce successful
crosslinking. With that system we were able to quickly
scan a crosslinked volume into corneal tissue, which
produced an increased corneal stiffness and blue
CAF, but the average power required to do this was
more than 17 times the ANSI limit (800 mW
compared to the 46.1 mW limit).10,11 By utilizing
amplified FS pulses, we were able to design a new
system that produces crosslinking using a much lower
average power, remaining under the ANSI limit. This
study explored the effects of amplified NLO CXL in
both ex vivo and in vivo models. To our knowledge, it
is the first report using amplified FS pulses for
photodynamic therapy that does not involve optical
breakdown.
During ex vivo experiments, it was discovered that
the laser scanning speed is logarithmically related to
the resulting CAF intensity. A speed of 15.5 mm/s was
Figure 7. In vivo corneal topography. Example images of corneal
topography measurements at baseline (A and C) and 2 months
after treatment (B and D) of the treated right eye (A and B) and the
control left eye (C and D).
Figure 8. Amplified NLO CXL induced corneal flattening. Graph
of corneal flattening measured as change in diopter of right versus
left eye (Total), right eye versus baseline (DR), and left eye versus
baseline (DL) over all time points. Corneal flattening decreased
dramatically after 1 week of healing, then reverted slightly and
began to flatten more steadily. Error bars represent standard
deviation.
Table 2. Corneal Flattening
Time Point, wk
0 1 2 4 8
Totala
Mean 0.1 1.4 0.8 1.0 1.2
SD 0.3 1.0 0.8 0.7 0.7
DRa
Mean 0 2.7b 2.8b 3.7b 5.1b
SD 0 1.1 0.8 0.7 1.2
DLa
Mean 0 1.2 1.9 2.6 3.8
SD 0 0.4 0.7 1.1 0.9
a Total refers to the DD (R-L) at each time point, DR refers
to the R minus baseline at each time point, and DL refers to
the L minus baseline at each time point.
b Refers to DR values, which are significantly lower than
corresponding DL values.
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found to have CAF comparable to traditional UVA
CXL. For this reason, the closest, easily attainable
speed (20 mm/s) was used for all other experiments.
We have also shown in this study that amplified NLO
CXL is still capable of producing a significant
increase in mechanical stiffness of corneal tissue: 1.6
times stiffer than control.
Many other studies have explored the in vivo
effects of UVA CXL and found marked effects on
corneal structure, specifically a flattening of at least 1
diopter lasting a year or longer.21–25 This has
increased the interest for use of corneal crosslinking
to treat low refractive errors. Like UVA CXL, NLO
CXL was a treatment originally designed to re-
strengthen corneas weakened by ectatic disease. This
study showed that it is possible to achieve flattening
with amplified NLO CXL as well, broadening the
scope of this treatment to treat low refractive errors as
well as corneal ectasia. Unlike UVA CXL, amplified
NLO CXL has the ability to treat the cornea in a
precise and customizable pattern at any depth within
the cornea. For example, 50 lm below the surface was
used in this study, with respect to the contact glass.
With this ability it could theoretically be possible to
customize corneal CXL based on individual corneal
topography. Also, if riboflavin could be imbibed into
the stroma without removing the epithelium, it would
be possible to crosslink below the intact epithelial
layer without damaging those cells during cross-
linking, resulting in a more effective and less painful
procedure. This study also showed repopulation of
the central CXL region of treatment by keratocytes as
early as 2 weeks post treatment. Our previous study
has shown that this repopulation is not attained
following UVA CXL out to 3 months post CXL,13
although others have noted earlier repopulation.26–28
One remaining mystery left unanswered by this
study is a physical explanation of why amplified FS
pulses are able to produce CXL so much more
efficiently than nonamplified pulses. Previous studies
using nonamplified pulses had required 800 mW, 10
nJ per pulse, to produce both CAF and increased
stiffening.10,11 In these studies, the scanning speed and
repetition rate were set in such a way that more than
45,000 pulses overlapped at any arbitrary volume
within the treatment area. Since each individual pulse
is 10 nJ, each volume would then encounter more
than 450 lJ over the course of the entire treatment. As
expected, no more than 8 mW of total power was
needed to produce CAF using 1 lJ pulses. It had been
assumed that several hundred of these pulses would
need to be overlapped, but unexpectedly, the CAF
spots seen in Figure 1 were created using a single pulse
totaling 1 lJ, well below what was required using
nonamplified pulses.
One explanation for this difference is the fluo-
rescence lifetime of riboflavin compared to the
timing of the pulses. Once a molecule of riboflavin
has absorbed photons, the time it requires to pass
into the excited triplet state is on the order of
nanoseconds, and the half-life of the excited triplet
state is around 15 ls. Any additional excitation
within this half-life may be absorbed, sending the
molecule back to an excited singlet state24 and
interrupting the production of free radicals entirely.
The nonamplified pulse system used in our previous
Figure 9. Long-term amplified NLO CXL. The images in (A) and
(B) are representative CAF and cellular-stained images of samples
after 2 months of in vivo healing. With the exception of one
sample (shown in C and D), cells stained with phalloidin and
ethidium homodimer had returned to the CXL region.
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studies had a repetition rate of 80 MHz, or 10 ns
between pulses. This is much shorter than the half-
life of the riboflavin triplet state and leaves little
time for the production of oxygen free radicals. We
suspect that much of the energy spent using an 80-
MHz oscillator may have been wasted sending
riboflavin molecules back and forth between excited
singlet and triplet states without ever creating free
radicals. The system used in this report had a pulse
separation of 10 to 20 ls within the half-life of the
riboflavin triplet state, thus creating far more
energy-efficient CXL. Future experiments will be
needed to test this theory.
One limitation of this study concerns measure-
ments of corneal flattening and effects following
NLO CXL. As has been noted previously, young
rabbits (,6 months) as used in this study are not
fully grown and show an age-related corneal
flattening as well as thickening throughout their
life.29 To account for potential age-related flattening,
which does not stabilize until 8 months of age,30 each
treated eye was compared to the contralateral
control eye.
Another limitation of this study is the reduced
measure of stiffening as compared to previous
iterations of this device. While this generation of
NLO CXL (using amplified pulses) was able to
produce a significant 1.6 times increase in corneal
elasticity, previous versions (using nonamplified
pulses) and UVA CXL produced a 2.6 and 2.9 times
increase, respectively, compared to control using the
same indentation testing technique and equipment.10
On its face, this difference may seem to indicate a
reduced stiffening effect with amplified NLO CXL
when compared to nonamplified NLO CXL or UVA
CXL, but this is likely not the case for many reasons.
First, amplified NLO CXL was able to induce CAF
intensity levels equal to and above UVA CXL,
which, according to previous studies, implies in-
creased stiffening.11 If amplified NLO CXL had
actually produced a lower stiffening effect than did
UVA CXL, it would be expected that CAF values
would also be lower. Also, as stated previously, the
CAF values measured in this study equaled those of
previous UVA CXL studies at a speed of 15.5 mm/s.
Despite this, a speed of 20 mm/s was used for
convenience, which could account for a small
portion of the difference. Finally, the CXL volume
was both thinner (approximately half) and posi-
tioned deeper than for previous studies.10,13 In all
previous studies, mechanical measurements were
performed on samples that had a CXL volume
positioned exactly at the surface of the stroma. This
places the indentation needle directly in contact with
the treated area. As illustrated in Figures 3, 6, and 9,
the CXL volume in this study was positioned deeper
into the stroma, leaving a volume of untreated tissue
above. Because the indentation needle was not
directly in contact with treated area during testing,
the results were slightly dampened. If the speed,
thickness, and depth could be adjusted to match
previous reports, it is likely the results would be
higher than reported in this study.
Conclusion
This study details both the development and
testing of a modified NLO CXL technique. By
utilizing amplified FS pulses, this technique was able
to achieve both ex vivo and in vivo corneal CXL on
par with nonamplified NLO CXL and traditional
UVA CXL.
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